Integrity Alliance LLC. Invests $596,000 in Natera, Inc. $NTRA

Integrity Alliance LLC. acquired a new position in Natera, Inc. (NASDAQ:NTRA) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 2,603 shares of the medical research company’s stock, valued at approximately $596,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Robinhood Asset Management LLC purchased a new position in shares of Natera in the 4th quarter worth about $12,981,000. JPMorgan Chase & Co. lifted its stake in shares of Natera by 9.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 11,628,914 shares of the medical research company’s stock valued at $1,871,914,000 after acquiring an additional 1,003,129 shares during the last quarter. New York State Common Retirement Fund lifted its stake in shares of Natera by 63.2% in the 3rd quarter. New York State Common Retirement Fund now owns 148,247 shares of the medical research company’s stock valued at $23,863,000 after acquiring an additional 57,400 shares during the last quarter. Krilogy Financial LLC bought a new stake in shares of Natera in the 3rd quarter valued at about $1,323,000. Finally, Zweig DiMenna Associates LLC lifted its stake in shares of Natera by 6.8% in the 3rd quarter. Zweig DiMenna Associates LLC now owns 132,500 shares of the medical research company’s stock valued at $21,329,000 after acquiring an additional 8,400 shares during the last quarter. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Natera news, CFO Michael Burkes Brophy sold 3,070 shares of the company’s stock in a transaction that occurred on Wednesday, April 29th. The stock was sold at an average price of $193.74, for a total transaction of $594,781.80. Following the completion of the transaction, the chief financial officer owned 58,291 shares of the company’s stock, valued at $11,293,298.34. This represents a 5.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider John Fesko sold 1,688 shares of the company’s stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $204.10, for a total value of $344,520.80. Following the transaction, the insider directly owned 187,511 shares of the company’s stock, valued at $38,270,995.10. The trade was a 0.89% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 41,356 shares of company stock worth $8,374,584. 5.63% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research firms have recently weighed in on NTRA. Morgan Stanley lowered their target price on Natera from $265.00 to $250.00 and set an “overweight” rating for the company in a research note on Tuesday, March 3rd. Wells Fargo & Company boosted their target price on Natera from $215.00 to $220.00 and gave the company an “equal weight” rating in a research note on Friday, May 8th. Robert W. Baird set a $265.00 target price on Natera in a research note on Friday, May 8th. Wall Street Zen lowered Natera from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Finally, William Blair began coverage on Natera in a research note on Tuesday, April 14th. They issued an “outperform” rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Natera presently has an average rating of “Moderate Buy” and a consensus target price of $256.60.

Key Natera News

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera announced a new collaboration with Diakonos Oncology to use Signatera in a Phase I/II study for refractory melanoma, expanding a key cancer-testing product into another clinical use case and reinforcing its oncology growth story. Article Title
• Positive Sentiment: Canaccord raised its price target on Natera to $250 from $200, signaling stronger confidence in the company’s outlook and helping fuel bullish sentiment. Article Title
• Positive Sentiment: Natera is also drawing attention from investors after commentary calling it a favorite stock idea for the rest of 2026, which adds to the momentum around the name. Article Title

Natera Price Performance

NTRA opened at $223.37 on Friday. The business has a 50 day simple moving average of $202.37 and a two-hundred day simple moving average of $215.69. The firm has a market capitalization of $31.99 billion, a price-to-earnings ratio of -137.04 and a beta of 1.57. Natera, Inc. has a one year low of $131.81 and a one year high of $256.36.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Thursday, February 26th. The medical research company reported $0.35 EPS for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.81. The business had revenue of $665.50 million during the quarter, compared to analyst estimates of $600.68 million. Natera had a negative return on equity of 14.74% and a negative net margin of 9.05%.During the same quarter in the prior year, the company posted ($0.41) EPS. As a group, sell-side analysts expect that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.